An Updated Review on Plant Derived Janus Kinase Inhibitors Against Rheumatoid Arthritis

DOI

10.2991/978-94-6463-813-4_5How to use a DOI?

Keywords

Plant Derived Compound; JAK-STAT pathway; Cytokines; Inflammations; Rheumatoid Arthritis

Abstract

Rheumatoid arthritis is the most disabling autoimmune condition with persistent inflammation and severe joint destruction. Research conducted in the last decade points to the JAK/STAT signaling pathway as a new contender in the management of RA. The new DMARDs that have been recently approved by the FDA as JAK/STAT pathway inhibitors have come into prominence over the recent years. However, the associated risks of thromboembolism, gastrointestinal side effects, liver damage, and other conditions such as tuberculosis and herpes zoster that come with the use of and administering DMARDs should not be overlooked. Furthermore, they are all considerably pricey, which renders them less suitable for widespread use. These restrictions allow the exploration of new JAK/STAT inhibitors obtained via natural sources which are safer, more cost-efficient, and better tolerated. This review emphasizes the premise of plant-derived JAK inhibitors becoming putative therapeutics of RA. Emodin, mangiferin, apigenin, quercetin, kaempferol etc. exhibit significant JAK inhibitory and anti-inflammatory effects among numerous natural compounds. Plant-derived inhibitors display improved safety profiles and less adverse effects compared to synthetic drugs. Here, we review the mechanisms of action of such natural compounds, their in vitro & in vivo efficacy, as well as the challenges we might face in the development process of RA therapies. Hence, the JAK inhibitors from natural products represent an interesting path forward, showing promise for safe and effective management of patients.

Copyright

© 2025 The Author(s)

Open Access

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

TY  - CONF
AU  - Anagh Mukherjee
AU  - Uttam Prasad Panigrahy
AU  - Bolay Bhattacharya
PY  - 2025
DA  - 2025/08/13
TI  - An Updated Review on Plant Derived Janus Kinase Inhibitors Against Rheumatoid Arthritis
BT  - Proceedings of the International symposium on Sustainable Drug Design and Nanoparticle development: Quantum and Computational Perspectives (SDDNDQCP 2025)
PB  - Atlantis Press
SP  - 42
EP  - 56
SN  - 2468-5739
UR  - https://doi.org/10.2991/978-94-6463-813-4_5
DO  - 10.2991/978-94-6463-813-4_5
ID  - Mukherjee2025
ER  -